We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)” (Abstract 11) was presented at the 2021 Genitourinary Cancers Symposium, 11–13 February 2021.
Prof. Axel Merseburger also discusses updates in immunotherapy in genitourinary cancers on our sister site, touchIMMUNOLOGY.
Questions
- Could you give us a brief overview of the TITAN phase III study? (00:17)
- What did the final TITAN analysis show in terms of efficacy, safety and health-related quality of life outcomes? (01:21)
- On the basis of these findings, what will be the likely place of apalutamide in combination with androgen deprivation therapy in the treatment paradigm for patients with metastatic castration-sensitive prostate cancer? (2:47)
Disclosures: Prof. Axel Merseburger has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 Genitourinary Cancers Symposium (Virtual), 11–13 February 2021.
Reference
Chi KN, Chowdhury S, Bjartell A, et al. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). J Clin Oncol. 2021;39(Suppl.6):11.
